The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease

Autor: William M. Smith, Pavur Sundaresan, Neville Bittar, Richard A. Stein, Kenneth Pomerantz, Puneet Narayan, Robert Tota, Arthur Mazzu, Stephen D. Nash, Udho Thadani, Sharon Larkin, Stephen P. Glasser
Rok vydání: 2002
Předmět:
Adult
Male
medicine.medical_specialty
medicine.drug_mechanism_of_action
Phosphodiesterase Inhibitors
Systole
Blood Pressure
Coronary Artery Disease
Placebo
Cardiovascular System
Piperazines
Angina
Coronary artery disease
Electrocardiography
Bruce protocol
Double-Blind Method
Erectile Dysfunction
Vardenafil Dihydrochloride
3'
5'-Cyclic-GMP Phosphodiesterases
Diastole
Heart Rate
Internal medicine
Heart rate
medicine
Humans
Sulfones
Exercise
Aged
Aged
80 and over
Cyclic Nucleotide Phosphodiesterases
Type 5
Cross-Over Studies
Exercise Tolerance
business.industry
Phosphoric Diester Hydrolases
Triazines
Imidazoles
Middle Aged
medicine.disease
Erectile dysfunction
Endocrinology
Treatment Outcome
Vardenafil
Cardiology
Exercise Test
Cardiology and Cardiovascular Medicine
business
Phosphodiesterase 5 inhibitor
medicine.drug
Zdroj: Journal of the American College of Cardiology. 40(11)
ISSN: 0735-1097
Popis: Objectives The effect of vardenafil, a potent and highly selective phosphodiesterase-5 (PDE5) inhibitor, on symptom-limited exercise time, time to first awareness of angina, and time to ischemic threshold (ST-segment depression ≥1 mm from baseline) during exercise tolerance testing (ETT) was examined in patients with stable coronary artery disease (CAD). Background Erectile dysfunction (ED) is common among men with CAD. PDE5 inhibition is increasingly the preferred treatment option for ED. However, the effect of PDE5 inhibition on exercise-induced ischemia in CAD patients has received limited prospective evaluation. Methods In this double-blind, crossover, single-dose multicenter study, 41 men with reproducible stable exertional angina due to ischemic CAD received vardenafil 10 mg or placebo, followed by ETT (5 to 10 metabolic equivalents [METS], Bruce protocol) 1 h postdose. Sublingual nitrate use was prohibited for ≥24 h pre- and postexercise study days. End points included symptom-limited treadmill exercise time, time to first awareness of angina, time to ischemic threshold, and safety. Results Relative to placebo, vardenafil 10 mg did not alter exercise treadmill time (427 ± 105 s vs. 433 ± 109 s, p = 0.39), or time to first awareness of angina (292 ± 110 s vs. 291 ± 123 s, p = 0.59), but significantly prolonged time to ischemic threshold (334 ± 108 s vs. 381 ± 108, p = 0.0004). At peak exercise, vardenafil 10 mg did not alter blood pressure, heart rate, or rate-pressure product relative to placebo. The most common adverse events (facial flushing and headache) were of mild or moderate intensity, and short-lived. Conclusions Vardenafil 10 mg did not impair the ability of patients with stable CAD to exercise at levels equivalent or greater than that attained during sexual intercourse (average of 2.5 to 3.3 METS).
Databáze: OpenAIRE
Externí odkaz: